Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.17 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 10.06 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 11.17 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.46B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.30 | 12.08 | 11.10 | 11.70 | 3,333,626 | -0.13 | -1.15% |
1 Month | 12.40 | 12.67 | 11.10 | 11.81 | 2,121,994 | -1.23 | -9.92% |
3 Months | 12.76 | 13.265 | 11.10 | 12.26 | 1,957,582 | -1.59 | -12.46% |
6 Months | 13.97 | 15.15 | 11.10 | 13.04 | 1,884,243 | -2.80 | -20.04% |
1 Year | 10.68 | 15.15 | 10.06 | 13.19 | 1,747,681 | 0.49 | 4.59% |
3 Years | 9.66 | 21.39 | 7.09 | 12.96 | 2,180,044 | 1.51 | 15.63% |
5 Years | 6.56 | 21.39 | 1.80 | 9.82 | 2,624,481 | 4.61 | 70.27% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |